Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...

Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

Cassava Sciences shares fell in premarket trading Friday after regulators said the company, along with two former executives, will pay more than $40 million to settle charges related to misleading ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...